Recombinant Human E-selectin (SELE)

What is E-selectin and what is its physiological role?

E-selectin (CD62E, also known as Endothelial Leukocyte Adhesion Molecule-1 or ELAM-1) is a 107-115 kDa cell surface glycoprotein that belongs to the selectin family of adhesion molecules. It is transiently expressed on vascular endothelial cells specifically in response to inflammatory cytokines such as IL-1β and TNF-alpha. E-selectin mediates the initial attachment of flowing leukocytes to the blood vessel wall during inflammation, allowing leukocytes to roll along the vascular endothelium in the direction of blood flow. This initial labile interaction is subsequently followed by stronger interactions involving other adhesion molecules like ICAM-1 and VCAM-1, eventually leading to leukocyte extravasation through the blood vessel wall into the extracellular matrix tissue .

E-selectin expression shows a characteristic temporal pattern, reaching peak expression at approximately 4 hours after activation and declining by 24 hours . This tightly regulated expression pattern makes E-selectin a critical early mediator in the inflammatory cascade.

How does recombinant human E-selectin compare to native E-selectin in terms of structure and function?

Recombinant human E-selectin proteins typically include the extracellular domain (from Trp22-Pro556) and often contain a C-terminal tag (such as a 6-His tag) for purification and detection purposes . When properly produced, recombinant E-selectin retains the functional properties of native E-selectin, including its ability to support leukocyte adhesion. Functional assays demonstrate that recombinant E-selectin supports the adhesion of cells like U937 human histiocytic lymphoma cells with an ED50 of 0.2-1 μg/mL .

The calcium dependency of E-selectin binding is preserved in recombinant forms, as demonstrated by control experiments showing binding inhibition when calcium is chelated by EDTA . Structurally, when analyzed by SDS-PAGE, recombinant human E-selectin His-tag proteins show bands at 84-109 kDa under reducing conditions and 60-84 kDa under non-reducing conditions, reflecting the glycosylation status and proper folding of the protein .

What are the optimal conditions for reconstitution and storage of recombinant human E-selectin?

Recombinant human E-selectin is typically supplied as a lyophilized protein from a 0.2 μm filtered solution in PBS. For optimal reconstitution, it should be reconstituted at a concentration of 500 μg/mL in PBS . To maintain protein stability:

• Use a manual defrost freezer and avoid repeated freeze-thaw cycles

• Store reconstituted protein at the recommended temperature (typically -20°C or -80°C)

• If carrier-free preparations are used (without BSA), special care should be taken to prevent protein degradation

For functional assays, it's critical to include calcium in buffers (typically 2mM CaCl2), as E-selectin binding is calcium-dependent. Control experiments should include EDTA (10mM) to demonstrate specificity of binding .

What methods are available for quantitative measurement of E-selectin interactions with its ligands?

Several methodologies have been developed for measuring E-selectin interactions with its ligands:

• Surface Plasmon Resonance (SPR): Real-time immunoprecipitation assays on SPR chips allow quantitative and rapid measurement of E-selectin interactions with its ligands following cell lysis. This technique enables measuring binding kinetics (on- and off-rates) of E-selectin with its ligands in their native post-translationally modified forms .

• Microarray Experiments: E-selectin proteins can be analyzed using glycan microarrays (such as Consortium for Functional Glycomics version 5.2 microarrays) to evaluate binding specificity. In this approach, microarray slides are rehydrated in appropriate buffer (e.g., TSM buffer containing 20 mM Tris-HCl, 150 mM NaCl, 2 mM CaCl2, and 2 mM MgCl2), and Fc-tagged E-selectin is applied. Bound selectins are detected with fluorescently-labeled anti-human IgG antibodies and quantified using appropriate scanning and software tools .

• Cell Adhesion Assays: Functional binding can be quantified by measuring the adhesion of E-selectin-binding cells (like U937) to immobilized recombinant E-selectin. The ED50 for this effect typically ranges from 0.2-1 μg/mL .

What are the major glycoprotein ligands for E-selectin on human and mouse cells, and how do they differ?

E-selectin binds to sialylated, fucosylated molecules on target cells, with significant species-specific differences in both identity and activity of these structures:

On human hematopoietic stem/progenitor cells (HSPCs), the CD44 glycoform called "HCELL" serves as a prominent E-selectin ligand, whereas it is not detected on mouse HSPCs. In contrast, the P-selectin glycoprotein ligand-1 (PSGL-1) glycoform called "CLA" shows more prominent E-selectin reactivity in mouse cells .

Functional studies using silencing or enforced expression approaches have demonstrated that CD44/HCELL significantly contributes to E-selectin binding in human cells. When CD44/HCELL was silenced via siRNA in human cells, E-selectin binding decreased by more than 50% under physiologic shear conditions. Conversely, enforced HCELL expression on mouse LSK cells significantly increased E-selectin adherence, resulting in more than 3-fold enhanced marrow homing in vivo .

What is the molecular basis for E-selectin recognition of its ligands, and how can this be modified experimentally?

E-selectin recognition of ligands depends on specific molecular interactions that can be manipulated through protein engineering. Computational approaches have been successfully used to engineer mutated forms of E-selectin with altered binding specificities.

A prime example is the engineering of E-selectin to recognize 6′-sulfo-sialyl Lewis X (6′-sulfo-sLex) instead of its natural ligand sialyl Lewis X (sLex). This was achieved through a double mutation (E92A/E107A) that:

• Removed unfavorable interactions with the 6′-sulfate group

• Introduced favorable interactions for the sulfate

• Eliminated favorable interactions with the endogenous ligand

Molecular dynamics simulations and energy calculations predicted these mutations would stabilize binding to the sulfated oligosaccharide. Glycan microarray screening confirmed the predicted specificity change, demonstrating that the mutant E-selectin bound to 6′-sulfo-sLex with negligible binding to its endogenous nonsulfated ligand sLex .

This approach illustrates how rational design assisted by computational approaches can create proteins with novel glycan recognition patterns, potentially useful for detecting disease-associated sulfated glycans.

How can different forms of recombinant E-selectin (monomeric vs. dimeric) impact experimental results?

The oligomeric state of recombinant E-selectin significantly affects its binding kinetics to ligands. Research has shown that:

• Monomeric E-selectin binds transiently to ligands like CD44/HCELL and PSGL-1 with fast on-rates and fast off-rates.

• Dimeric E-selectin interacts with the same ligands with remarkably slower on-rates and off-rates .

This difference in binding kinetics has important implications for experimental design. When studying transient interactions that mimic physiological rolling adhesion, monomeric E-selectin may provide more relevant data. Conversely, dimeric E-selectin may be more suitable for applications requiring stable binding, such as detecting low-abundance ligands.

Researchers should carefully consider which form to use based on their specific experimental objectives and ensure consistent use of either monomeric or dimeric forms throughout comparative studies to avoid misinterpretation of results.

What is the role of E-selectin in angiogenesis and how can this be analyzed experimentally?

E-selectin has been implicated in angiogenesis regulation, particularly in mediating the antiangiogenic activity of endostatin (a 20-kDa fragment of collagen XVIII). Evidence suggests that E-selectin is required for endostatin's inhibitory effects on blood vessel formation .

This relationship can be analyzed using various experimental approaches:

• In vivo corneal micropocket assays: Studies have shown that recombinant endostatin administered via osmotic pump inhibits basic fibroblast growth factor-induced angiogenesis in wild-type mice but not in E-selectin-deficient mice .

• Ex vivo aortic ring assays: Endostatin inhibits vascular endothelial growth factor (VEGF)-stimulated endothelial sprout formation from aortic rings of wild-type mice but not from E-selectin-deficient mice .

• In vitro cell migration assays: Human endothelial cells become more sensitive to inhibition by endostatin in VEGF-induced cell migration assays when E-selectin is induced by inflammatory stimuli like IL-1β or lipopolysaccharide .

To isolate E-selectin's role from other consequences of endothelial activation, researchers have used adenoviral E-selectin expression constructs to transduce human umbilical vein endothelial cells. These transduced cells show increased sensitivity to endostatin, and this effect requires the E-selectin cytoplasmic domain . This suggests that E-selectin may be a useful predictor and modulator of endostatin efficacy in antiangiogenic therapy.

What are the key considerations for validating E-selectin ligands on human cells where genetic manipulation is challenging?

Identifying and validating E-selectin ligands on human cells presents unique challenges because gene deletion/silencing approaches and knockout models are less feasible than in mouse systems. To address this, researchers can employ a combination of strategies:

• Real-time immunoprecipitation on SPR chips: This powerful complementary approach allows direct measurement of E-selectin interaction with its ligands in a quantitative and rapid manner following cell lysis. Endogenous E-selectin ligands in their native post-translationally modified form are captured with high specificity from whole cell lysates via surface-immobilized monoclonal antibodies (mAbs) .

• RNA interference approaches: Though more challenging in primary human cells, siRNA targeting of candidate ligands (like CD44) can be used to assess their functional contribution to E-selectin binding. Under physiologic shear conditions, CD44/HCELL-silenced human cells show striking decreases (>50%) in E-selectin binding .

• Exoglycosylation: Enforcing expression of specific glycoforms through exoglycosylation provides a complementary approach to silencing. This method can be particularly useful for confirming the role of specific glycosylation patterns in E-selectin binding .

• Blocking antibodies: Although no monoclonal antibodies against glycoproteins that block binding to E-selectin have been identified to date, developing such tools remains an important methodological goal for testing the physiologic functions of candidate E-selectin ligands on human cells .

How can researchers ensure the functional activity of recombinant E-selectin in experimental systems?

Ensuring the functional activity of recombinant E-selectin is crucial for experimental validity. Researchers should implement the following approaches:

• Calcium dependency verification: Include control experiments with EDTA (typically 10mM) instead of calcium in binding buffer to demonstrate calcium-dependent binding, which is a hallmark of functional selectins .

• Cell adhesion assays: Confirm that recombinant E-selectin supports the adhesion of known E-selectin-binding cells such as U937 human histiocytic lymphoma cells. The ED50 for functional E-selectin is typically 0.2-1 μg/mL .

• SDS-PAGE analysis: Verify protein integrity through SDS-PAGE under reducing and non-reducing conditions. Functional recombinant human E-selectin typically shows bands at 84-109 kDa and 60-84 kDa, respectively .

• Glycan array binding: Validate binding specificity using glycan arrays containing known E-selectin ligands like sLex. This approach is particularly important when working with engineered variants of E-selectin .

• Flow-based assays: Since E-selectin mediates rolling adhesions under flow conditions in vivo, flow-chamber assays that mimic physiological shear stress provide the most relevant functional validation. These assays can distinguish between E-selectin-mediated transient interactions and more stable adhesions mediated by other molecules .

How might engineered E-selectin variants be applied in glycan biomarker detection and disease monitoring?

Engineered E-selectin variants with altered binding specificities represent promising tools for detecting disease-associated glycans. The successful creation of an E-selectin double mutant (E92A/E107A) that specifically recognizes 6′-sulfo-sLex demonstrates the feasibility of this approach .

Potential applications include:

• Cancer biomarker detection: Altered glycosylation patterns are hallmarks of many cancers. Engineered E-selectin variants could detect specific cancer-associated glycans like sulfated glycans that are upregulated in certain malignancies.

• Inflammatory disease monitoring: Custom E-selectin variants could detect glycan changes associated with inflammatory conditions, potentially providing more specific markers than general inflammation indicators.

• Glycan array-based diagnostics: Libraries of engineered E-selectin proteins with different specificities could be developed for comprehensive glycan profiling of patient samples, potentially identifying disease-specific glycosylation signatures.

• In vivo imaging: Labeled E-selectin variants with specificity for disease-associated glycans could potentially serve as targeting molecules for molecular imaging applications.

The rational design approach using computational methods to predict mutations that alter glycan recognition specificity provides a template for creating additional E-selectin variants recognizing other clinically relevant glycan structures .

What are the implications of species-specific differences in E-selectin ligands for translational research?

The significant differences between human and mouse E-selectin ligands have important implications for translational research:

• Model selection: The prominent role of HCELL in human but not mouse cells suggests that mouse models may not fully recapitulate human E-selectin-dependent processes. Researchers should carefully consider these differences when selecting animal models and interpreting results .

• Hematopoietic stem cell transplantation: Since HCELL significantly contributes to human HSPC binding to E-selectin and marrow homing, strategies to optimize HSPC engraftment may differ between species. Enforced HCELL expression on mouse cells increased marrow homing more than 3-fold, highlighting potential therapeutic approaches for enhancing engraftment in clinical settings .

• Drug development: Therapeutics targeting E-selectin interactions may need to address different ligands depending on whether the target is human or mouse E-selectin. This has implications for preclinical testing and translation to clinical applications.

• Biomarker development: Species differences suggest that biomarkers based on E-selectin ligand expression or modification may not directly translate between mice and humans.

These species-intrinsic differences underscore the need for complementary approaches using both human samples and appropriate animal models in E-selectin research, particularly when developing therapeutics targeting this pathway .